Published Manuscripts
Spencer, A., Walker, P., Asvadi, P. et al. A preliminary study of the anti-κ myeloma antigen monoclonal antibody KappaMab (MDX-1097) in pretreated patients with κ-restricted multiple myeloma. Blood Cancer J. 2019; 9: 58.
https://doi.org/10.1038/s41408-019-0217-5
Keywords: KappaMab | Clinical Trial | Kappa-type multiple myeloma
Asvadi, P., Cuddihy, A., Dunn, R.D., et al. MDX‐1097 induces antibody‐dependent cellular cytotoxicity against kappa multiple myeloma cells and its activity is augmented by lenalidomide. Br J Haematol. 2015; 169: 333-343.
https://doi.org/10.1111/bjh.13298
Keywords: KappaMab | In vitro | ADCC | Free light chains | Lenalidomide
Hutchinson, A.T., Jones, D.R., Raison, R.L. Preclinical and clinical development of an anti-kappa free light chain mAb for multiple myeloma. Molecular Immunology. 2015; 67: 89-94.
https://doi.org/10.1016/j.molimm.2015.04.013
Keywords: Review | KappaMab/MDX-1097
Hutchinson, A.T., Jones, D.R., McCauley Winter, P., et al. Cell membrane associated free kappa light chains are found on a subset of tonsil and in vitro-derived plasmablasts. Human Immunol. 2014; 75: 986-990.
https://doi.org/10.1016/j.humimm.2014.08.196
Keywords: KappaMab/MDX-1097 | KMA expression in tissues
Hutchinson, A.T., Malik, A., Berkahn, M.B., et al. Formation of assemblies on cell membranes by secreted proteins: molecular studies of free λ light chain aggregates found on the surface of myeloma cells. Biochem J. 2013; 454: 479-489.
https://doi.org/10.1042/BJ20130575
Keywords: Myeloma Surface Antigen | Lambda Myeloma Antigen | Cell-suface lambda free light chain
Hutchinson, A.T., Alexova, R., Bockhorni, V., et al. Characterization of a unique conformational epitope on free immunoglobulin kappa light chains that is recognized by an antibody with therapeutic potential. Molecular Immunology 2011; 48: 1245-1252.
https://doi.org/10.1016/j.molimm.2011.03.003
Keywords: KappaMab | K-1-21 or mKap | Immunoglobulin light chain | Epitope
Hutchinson, A.T., Ramsland, P.A., Jones, D.R., et al. Free Ig light chains interact with sphingomyelin and are found on the surface of myeloma plasma cells in an aggregated form. J Immunol. 2010; 185 (7): 4179–4188.
https://doi.org/10.4049/jimmunol.1001956
Keywords: KappaMab | In vitro | Free light chains | K-1-21 or mKap | Immunoglobulin light chain | Epitope
Dunn, R.D., Weston, K.M., Longhurst, T.J., et al. Antigen binding and cytotoxic properties of a recombinant immunotoxin incorporating the lytic peptide, melittin. Immunotechnology. 1996; 2: 229-40.
Keywords: K-1-21 or mKap
Goodnow, C.C. and Raison, R.L. Structural analysis of the myeloma-associated membrane antigen KMA. J Immunol. 1985; 135(2): 1276-1280.
Keywords: KappaMab | K-1-21 or mKap
Walker, K.Z., Boux, H.A., Hayden, G.E., et al. (1985). A monoclonal antibody with selectivity for human kappa myeloma and lymphoma cells which has a potential as a therapeutic agent. In: Microenvironments in the Lymphoid System. Editor: G.G.B Klaus, Plenum Publishing Corporation.
Keywords: Free light chains | K-1-21 or mKap
Raison, R.L. and Boux, H.A. Conformation dependence of a monoclonal antibody defined epitope on free human kappa chains. Mol Immunol. 1985; 22(12): 1393-98.
Keywords: K-1-21 or mKap | Epitope
Walker, K.Z., Hayden, G.E., Goodnow, C.C., et al. Co-expression of an epitope on human free κ-light chains and on a cytoplasmic component in activated T cells. J Immunol. 1985; 134(2): 1059-64.
Keywords: In vitro | K-1-21 or mKap
Boux, H.A., Raison, R.L., Walker, K.Z., et al. The surface expression of a tumor-associated antigen on human kappa myeloma cells. Eur. J Immunol. 1984; 14: 216-222.
Keywords: In vitro | Free light chains | K-1-21 or mKap | Epitope
Boux, H.A., Raison, R.L., Walker, K.Z., et al. A tumour-associated antigen specific for human kappa myeloma cells. J Exp Med. 1983; 158(5): 1769-74.
Keywords: In vitro | Free light chains | K-1-21 or mKap | Epitope
Conference Presentations
Li J, Haynes N, Cummins K, et al. Cellular Immunotherapy Targeting Kappa Myeloma Antigen for the Treatment of Multiple Myeloma. Cancer Res. 2023; 83 (7_Supplement): 4074.
Keywords: Kappa Myeloma Antigen | KMA.CAR T Cells | In Vitro | In Vivo | Multiple Myeloma
Sartor, M., Gottlieb, DJ., and Dunn, R. Novel Antigens LMA and KMA are Expressed on Malignant Bone Marrow Plasma Cells from Patients with Relapsed Refractory Multiple Myeloma and Plasma Cell Dyscrasias. Blood. 2022; 140 (Supplement 1): 4211–4212.
Keywords: KappaMab | LambdaMab | Plasma Cell Dyscrasias | Multiple Myeloma | KMA | LMA
Sartor, M., Dunn, R., and Gottlieb, D.J. Expression of kappa myeloma antigen (KMA) and lambda myeloma antigen (LMA) on bone marrow plasma cells in patients with multiple myeloma: implications for antibody and cellular therapy. Myeloma Australia 4th National Myeloma Workshop Event; Pathways to a Cure. 21-23 October 2022. Kalorama, Victoria, Australia.
Keywords: KappaMab | LambdaMab | Plasma Cell Dyscrasias | Multiple Myeloma | KMA | LMA
Harrison, S, Li J, Haynes N, et al. Lentiviral generation of CAR-T cells targeting kappa myeloma antigen for the treatment of multiple myeloma. Myeloma Australia 4th National Myeloma Workshop Event; Pathways to a Cure. 21-23 October 2022. Kalorama, Victoria, Australia.
Keywords: Kappa Myeloma Antigen | KMA.CAR T Cells | In Vitro | In Vivo | Multiple Myeloma
Sartor, M., Hu, D., Lemarchand, T.X., et al. A Novel B Cell Antigen Designated Lambda Myeloma Antigen (LMA) Has Been Identified Using Two Fully Human Monoclonal Antibodies (Mabs) That Bind to Similar Epitopes on Plasma Cells from Patients with Plasma Cell Dyscrasias. Blood. 2021; 138 (Supplement 1):1595.
Keywords: KappaMab | LambdaMab | Plasma Cell Dyscrasias | 10B3 | 7F11
Kalff, A., Shortt, J., Yuen, F., et al. A sequential cohort study comparing KappaMab alone to KappaMab, lenalidomide and low dose dexamethasone in kappa-restricted relapsed refractory (RR) multiple myeloma (AMaRC 01-16). Blood. 2019; 134 (Supplement 1): 3144.
Keywords: KappaMab | Clinical Trial | Kappa-type multiple myeloma | Lenalidomide
Gowrishankar, K., Dunn, R., Gottlieb, D., and Micklethwaite, K. CAR T-cells targeting the kappa myeloma antigen for the treatment of multiple myeloma. Cancer Res. 2018; 78 (13_Supplement):3572.
Keywords: CAR T cells | Kappa-type multiple myeloma
Dunn, R., Spencer, A., Augustson B., et al. Phase 2a, open-label, multi-dose study of the anti-kappa monoclonal antibody, MDX-1097, in relapsed kappa-chain restricted multiple myeloma with stable measurable disease. Haematologica. 2013; 98(s1):776.
Keywords: KappaMab / MDX-1097 | Clinical Trial | Kappa-type multiple myeloma KMA
Asvadi, P., Jennings, C., Jiang, V., et al. Identification and characterization of lambda myeloma antigen, LMA, as a therapeutic target in lambda type multiple myeloma. Haematologica. 2013; 98(s1):756.
Keywords: Lambda-type multiple myeloma / LMA
Cuddihy, A.R., Khong, T., Dunn, R., et al. The anti-kappa monoclonal antibody MDX-1097 cooperates with lenalidomide to enhance antibody-dependent cell cytotoxicity of multiple myeloma cells.
Cancer Res. 2012; 72 (8_Supplement): 2522.
Keywords: KappaMab / MDX-1097 | In vitro | ADCC / Apoptosis | Lenalidomide
Cuddihy, A.R., Khong, T., Dunn, R., et al. The anti-kappa monoclonal antibody MDX-1097 synergizes with immunomodulatory drugs to enhance antibody-dependent cell cytotoxicity of multiple myeloma cells. Blood. 2012; 120 (21): 4012.
Keywords: KappaMab / MDX-1097 | In vitro | ADCC / Apoptosis
Cuddihy, A. R., Khong, Asvadi, P., et al. HDACi and IMiDs enhance anti-myeloma activity of the anti-KMA monoclonal antibody
MDX-1097. Clin Lymph Myel Leuk. 2013; 13(supplement 1): P-281.
Keywords: KappaMab | MDX-1097 | ADCC
Spencer, A., Walker, P., Asvadi, P., et al. A phase I study of the anti-kappa monoclonal antibody, MDX-1097, in previously treated multiple myeloma patients. J Clin Oncol. 2010; 28(15_suppl):8143.
Keywords: KappaMab / MDX-1097 | Clinical Trial | Kappa-type multiple myeloma / KMA
Wong, M., Asvadi, P., Dunn, R., et al. MDX-1097 Binds specifically to kappa myeloma cells and anti-tumour activity is mediated by multiple effector cells. Blood. 2009; 114(22): 1846.
Keywords: KappaMab / MDX-1097 | In vitro
Jones, D.R. Asvadi, P., Raison, R.L., et al. Expression of the kappa myeloma antigen on the cell surface of bone marrow aspirates from Waldenstrom’s Macroglobulinemia patients. Haematologica. 2007; 92(s2): PO-1207.
Keywords: KappaMab / MDX-1097 | In vitro | Waldenstrom's macroglobulinemia
Alexova, R., Hutchinson, A., Jones, D.R., et al. Characterisation of a novel conformational epitope on human free kappa light chains defined by a monoclonal antibody with therapeutic potential for multiple myeloma. The Australian and New Zealand Society for Immunology meeting. Sydney Australia, 2007.
Keywords: Free light chains | K-1-21 or mKap | Epitope
Raison, R.L., Jones, D.R., Asvadi, P., et al. A chimeric monoclonal antibody specific for kappa multiple myeloma plasma cells mediates ADCC of tumor cells. Haematologica. 2005; 90(s1) PO-206.
Keywords: K-1-21 or mKap | In vivo model
Asvadi, P., Jones, D.R., Dunn, R., et al. A monoclonal antibody specific for free human kappa light chains induces apoptosis of multiple myeloma cells and exhibits anti-tumor activity in vivo. Blood. 2004; 104(11): 2416.
Keywords: K-1-21 or mKap | In vivo model | ADCC / Apoptosis